Karin Jooss - 02 Feb 2023 Form 4 Insider Report for Gritstone bio, Inc.

Role: Executive Vice President and Head of Research and Development
Signature: /s/ Vassiliki (Celia) Economides, Attorney-in-Fact for Karin Jooss
Issuer symbol: N/A
Transactions as of: 02 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Feb 2023, 16:32:30 UTC
Previous filing: 13 Jun 2022
Next filing: 07 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GRTS	Common Stock	Award	$0	+252,763	+67%	$0.000000	630,147	02 Feb 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents Restricted Stock Units ("RSUs") 170,366 of which vest semi-annually over four years and 82,397 of which vest annually over two years from February 1, 2023, in each case, subject to the Reporting Person's continuous service to the Issuer on each such date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2	Includes 252,763 RSUs which are subject to vesting.

Remarks:

Executive Vice President and Head of Research and Development